

## SOFT TISSUE SARCOMAS

### ISIORT POOLED ANALYSIS

255 PATIENTS  
TREATED WITH IOERT + ADJUVANT EBRT  
MEDIAN FOLLOW-UP: 61 MONTHS

	<b>5-yr overall survival</b>	<b>5-yr local control</b>
Resect. status		
R0	80%	85%
R1/x	71%	60%
R2	23% $p < 0.01^*$	45% $p < 0.01^*$
Grading		
G1/2	96%	80%
G3/4	53% $p < 0.001^{**}$	67% n.s.
Pri. disease	78%	73%
Recur. disease	64% n.s.	69% n.s.
Tumor size		
< 5 cm	88%	88%
> 5 cm	69% n.s.	67% n.s.
IOERT dose		
< 15 Gy	58%	50%
$\geq 15$ Gy	78% $p < 0.05$	85% $p < 0.05$
EBRT dose		
< 45 Gy	72%	67%
$\geq 45$ Gy	78% n.s.	82% n.s.
* For R0+R1/X vs. R2      ** For G1/2 vs. G3/4		

## Conclusions

Combination of IOERT and EBRT results in  
-good functional outcome  
-low incidence of side effects and  
-reduced overall treatment time  
without compromising local control

R1/X-resection can be compensated by IOERT + EBRT  
In R2-situations IOERT should be employed with  
palliative intention only.